ARIAD Pharmaceuticals, Inc. has exercised its option with Merck & Co. to co-promote ridaforolimus, an investigational mTOR inhibitor, in the sarcoma indication, upon approval in the U.S. Under the license agreement dating back to May 2010 for the development, manufacture and commercialization of ridaforolimus in oncology, ARIAD has the option to co-promote ridaforolimus with as much as 20% of the sales effort for the product in all indications in the U.S. “The decision to co-promote ri...